The recently commercially produced specific enzyme phenylalanine dehydrogenase offers many possibilities for applications in screening programs (7) and for follow-up of dietary therapy (8) Comparative column chromatographic estimations of phenylalanine in plasma, whole blood, native and paper-dried capillary blood of healthy children and adults, and patients with hyperphenylalaninemia. 
A study was carried out to assess the best use of biochemical bone markers to exclude metastases in patients with breast cancer. Urinary galactosyl-hydroxylysine and serum alkaline phosphatase were used to monitor bone resorption and deposition, respectively. Hydroxyproline was also measured. In a selected population of patients, possibly affected by metastases on the basis of scintigraphic examination, which is highly sensitive but poorly specific, we assessed the efficiency of the markers by a double statistical analysis. In this group, the only marker able to predict metastases was galactosylhydroxylysine. patients, who were divided into three groups according to their scintigraphic and radiological data; we have included serum total alkaline phosphatase (ALP; EC 3.1.3.1) as an index of bone formation, in an attempt to increase the efficiency of the diagnosis.
AdditIonal

Patients and Methods
Patients
Three age-matched groups of women with breast cancer were selected for this study: 28 patients with clinical, radiological, and scintigraphic evidence of osteolytic, osteoblastic, or mixed bone metastases (M+), and 41 without such evidence (Mo). A third group of 32 patients (Mx) had positive scintigraphic results without clinical or radiological evidence of metastases.
The patients had no previous history of any skeletal or hepatic disease and were not receiving drugs that might influence skeletal metabolism, e.g., corticosteroids, calcitonm, diuretics, or vitamin D metabolites. After mastectomy, the patients were investigated every 3 months with clinical, radiological, and laboratory tests. Bone scintigraphy with #{176}Tc was repeated yearly.
Procedures
Urine collection and measurements.
A 24-h urine sample was collected from each patient every 3 months for measurements of creatinine, HYP, and GHYL. The collection was started after 3 days of a collagen-free diet.
Borate (1 g/L) was added to the urine samples to prevent bacterial growth. The samples were stored at -30 #{176}C until analyzed.
GHYL was measured by HPLC of dansylated urine samples as previously reported values (10) , and for each value we estimated the specificity (as the ratio between truenegatives and the sum of true negatives and false positives) and the sensitivity (as the ratio between the true positives and the sum of true positives and false negatives). The sensitivity was then plotted vs (100 -specificity) to produce a receiver-operating Characteristic (ROC) curve for each assay. The diagnostic efficiency was estimated as the area under the ROC curve (10).
To evaluate the capacity of GHYL, HYP, and ALP to discriminate between Mo and M+ and between Mx and Mx converting to M+, we used logistic-regression analysis of the posterior probabilities for prediction from the logistic model (11).
Results
Because bone metastases in the patients of this study were identified by roentgenography as osteolytic (75%), osteoblastic (21%), and mixed type (4%), we also included the moat used marker of osteoblastic activity, ALP, in our attempt to increase the predictive capacity of the tests. Figure 1 shows the values of urinary GHYL and HYP concentrations and serum ALP activity in the three groups of patients. All markers are significantly greater in the M+ patients than in the patients of the In another approach to assess the value of each marker, we examined the diagnostic efficiency of the tests, drawing ROC curves separately for each marker and for combinations of the markers (Figure 2) . The largest area under the curve, i.e., the best diagnostic efficiency (0.89), was provided by GHYL, followed by ALP (0.82) and HYP (0.78). However, the combination of GHYL and ALP gave an even better value (0.97), covering essentially all the area. Combining GHYL and ALP with HYP did not increase the efficiency of the tests.
We also used a weighted multivariate logistic regression to predict metastases in patients with breast cancer. We tested the logistic model's improvement for each variable (GHYL, ALP, and HYP) separately and for all the variables together. Figure 2 in the logistic-equation model showed a significant contribution to predict metastases for the variables GHYL (P = 0.01) and ALP (P = 0.02) but not for HYP (P = 0.53).
Using the data illustrated by
We also monitored the patients in the Mx group. After 18 months, 10 Mx patients (31%) had converted to M+. We then divided the original Mx group data according to whether each subject's status remained unchanged or converted to M+, and used the ROC curve (Figure 3 ) and the logistic model described above to analyze the predictive capacity of the tests. GHYL provided the best efficiency (0.83) and again gave a significant contribution to predict metastases (P = 0.03), whereas ALP (efficiency = 0.64) was not useful (P = 0.19).
Discussion
Bone markers used in the present study appeared to agree with the data provided by the conventional means of diagnosis, because they had average normal values in Mo patients and increased values in M+ patients. Interestingly, in the Mx group, characterized only by positive scintigraphy, the concentrations of the markers were in the normal range, suggesting that metastases were either absent or quite small (below the detection limit of roentgenography).
The present investigation confirms the data we already published (8) and shows the utility of using the combination of a specific bone resorption marker and negatives is almost negligible. Our findings also confirm the poor specificity of HYP, which did not increase the efficiency when combined with the other markers. When we focused on the evolution of the patients of Mx group, we found that the efficiency of the tests in this group was slightly lower for GHYL (0.83), and lower for ALP (0.64) and that the interaction between GHYL and ALP did not increase the area under the ROC curve ( Figure 3) . Moreover, the multivariate logistic regression approach showed that the only predictive variable for metastases was GHYL (P = 0.03). We believe this apparent discrepancy reflects the different populations of patients that form the Mo and the Mx group. The Mx group is not as homogeneous as the Mo group, because some patients in the former group may indeed have metastases, even if at the moment these could be detected only by scintigraphy.
Because scintigraphy is much more sensitive than the biochemical markers, the rate of false positives (true metastates despite the biochemical markers being in the normal range) will affect the efficiency of the tests when compared with their performance for the Mo and M+ groups.
In conclusion, the ROC curve and the multivariate logistic regression analysis show that also in the Mx group, some of whom converted to the M+ group, the only predictive marker for metastases remains GHYL.
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